possibl
identifi
genet
fingerprint
caus
agent
emerg
viral
diseas
often
extraordinari
speed
suitabl
therapi
develop
equival
speed
drug
discoveri
requir
inform
goe
beyond
knowledg
viral
genom
peptid
howev
may
repres
special
opportun
envelop
virus
fusion
viral
target
cell
membran
obligatori
step
life
cycl
class
fusion
protein
harbor
region
repeat
pattern
amino
acid
heptad
repeat
hr
play
key
role
fusion
hrderiv
peptid
enfuvirtid
clinic
use
hiv
block
process
characterist
sequenc
pattern
hr
easili
identifi
genom
mean
comput
program
provid
sequenc
candid
peptid
inhibitor
directli
genom
inform
moreov
simpl
chemic
modif
attach
cholesterol
group
dramat
increas
antivir
potenc
hrderiv
inhibitor
simultan
improv
pharmacokinet
enhanc
provid
dimer
cholesterolconjug
peptid
exampl
report
far
includ
inhibitor
retrovirus
paramyxovirus
orthomyxovirus
henipavirus
coronavirus
filovirus
virus
vivo
efficaci
demonstr
suitabl
anim
model
combin
bioinformat
lead
identif
potencypharmacokinet
improv
provid
cholesterol
conjug
may
form
basi
rapid
respons
strategi
develop
emerg
cholesterolconjug
therapeut
would
immedi
follow
avail
genet
inform
new
envelop
viru
spectrum
infecti
diseas
threaten
human
health
rapidli
broaden
number
previous
unknown
condit
emerg
sinc
exce
new
diseas
discov
averag
year
accord
world
health
organ
report
year
record
worldwid
epidem
event
occur
comprehens
examin
episod
emerg
infecti
diseas
outbreak
control
report
bia
came
conclus
incid
event
increas
significantli
time
viral
diseas
particular
addit
constant
fear
new
wave
pandem
influenza
list
emerg
reemerg
virus
includ
hiv
time
manuscript
final
largest
longest
outbreak
ebola
viru
still
spread
latter
viru
togeth
nipah
viru
hantaviru
lassa
viru
marburg
viru
center
diseas
control
prevent
list
bioterror
agent
virus
therapeut
option
limit
complet
absent
best
descript
featur
outbreak
novel
viru
come
sar
pandem
first
major
emerg
diseas
threat
centuri
short
period
global
alert
march
announc
pandem
juli
sar
affect
peopl
caus
death
disrupt
intern
travel
cost
huge
busi
loss
sar
present
mani
featur
fear
pandem
diseas
respiratori
diseas
transmit
person
person
long
asymptomat
incub
period
symptom
similar
commonplac
ill
time
first
appear
caus
agent
sarsassoci
coronaviru
unknown
neither
diagnost
test
specif
treatment
intern
respons
new
threat
extrem
efficaci
lead
isol
sarscov
sequenc
genom
record
time
week
measur
prove
efficaci
contain
diseas
isol
quarantin
travel
surveil
increas
person
hygien
person
protect
equip
mask
glove
eyeglass
pharmacolog
treatment
howev
expert
panel
review
conclud
possibl
determin
whether
treatment
use
sarsinfect
patient
benefit
suggest
treatment
might
actual
harm
sar
case
vividli
illustr
abil
quickli
isol
genet
fingerprint
caus
agent
new
viral
diseas
match
abil
develop
suitabl
treatment
surpris
drug
discoveri
typic
requir
addit
inform
simpli
deriv
knowledg
viral
genom
background
peptid
may
repres
special
case
envelop
virus
gener
possibl
identifi
sequenc
candid
peptid
inhibitor
directli
genom
inform
envelop
virus
fusion
viral
target
cell
membran
repres
obligatori
step
life
cycl
interf
process
wellestablish
therapeut
strategi
led
develop
peptid
fusion
inhibitor
enfuvirtid
fuzeon
also
known
roch
basel
switzerland
clinic
use
hiv
viral
fusion
mediat
special
protein
harbor
structur
motif
consist
repeat
pattern
seven
amino
acid
heptad
repeat
hr
preval
class
class
fusion
protein
typic
two
hr
region
first
one
close
nterminu
hrn
adjac
fusion
peptid
second
one
close
cterminu
hrc
immedi
preced
transmembran
domain
gener
accept
key
intermedi
viral
fusion
socal
prehairpin
intermedi
bridg
viral
cell
membran
hrn
hrc
region
separ
hrn
form
trimer
coil
coil
figur
fold
hrc
onto
hrn
trimer
lead
format
sixhel
bundl
process
two
membran
brought
close
apposit
lead
fusion
figur
peptid
correspond
sequenc
hr
region
bind
prehairpin
intermedi
prevent
transit
block
fusion
figur
mechan
inhibit
enfuvirtid
appli
sever
peptid
deriv
hr
region
mani
virus
characterist
sequenc
pattern
hr
provid
import
advantag
develop
peptidebas
antivir
hr
easili
identifi
comput
program
eg
learncoil
multicoil
case
sarscov
hr
region
immedi
identifi
led
develop
peptid
inhibitor
absenc
structur
inform
fusion
protein
came
later
larg
confirm
predict
pathway
drug
develop
offer
opportun
develop
specif
antivir
short
timefram
howev
hrderiv
peptid
display
antivir
potenc
hiv
fusion
inhibitor
enfuvirtid
major
factor
play
differ
fusion
kinet
virus
unlik
hiv
transit
hairpin
intermedi
rapidli
offer
shorter
window
opportun
peptid
inhibitor
accordingli
show
reduc
potenc
peptid
lead
deriv
genom
inform
insuffici
potenc
necessari
modifi
peptid
engin
strategi
although
often
success
may
time
consum
altern
approach
requir
chang
nativ
hr
sequenc
exploit
role
cholesterol
viral
fusion
cholesterol
play
key
role
fusion
bud
envelop
virus
hiv
studi
case
shown
cholesterol
deplet
virusinfect
cell
suppress
viru
product
deplet
cholesterol
either
virion
target
cell
inhibit
viruscel
fusion
hiv
abl
influenc
cholesterol
metabol
host
cell
lipid
membran
highli
enrich
cholesterol
moreov
link
establish
low
level
cholesterol
antigenpres
cell
statu
longterm
nonprogressor
rare
infect
individu
control
diseas
progress
absenc
antiretrovir
therapi
role
cholesterol
viral
fusion
relat
role
membran
fluiditi
particular
format
lipid
raft
accordingli
composit
lipid
membran
hiv
highli
enrich
cholesterol
sphingomyelin
moreov
primari
receptor
hiv
enrich
lipid
raft
ingallinella
et
al
propos
addit
cholesterol
group
hrderiv
peptid
would
augment
affin
membran
particular
cholesterolrich
lipid
raft
result
increas
local
concentr
site
action
would
translat
enhanc
antivir
potenc
figur
b
applic
concept
hrderiv
peptid
yield
cholesterol
group
attach
via
thioether
bond
side
chain
cy
residu
ad
cterminu
interven
glysergli
spacer
cholesterol
conjug
brought
dramat
improv
antivir
potenc
depend
viral
strain
test
potent
unconjug
potent
enfuvirtid
improv
appar
cholesterol
substitut
palmit
acid
lipid
poorer
membran
anchor
enrich
lipid
raft
numer
exampl
sinc
accumul
cholesterol
conjug
improv
antivir
potenc
hrderiv
peptid
mani
envelop
virusesthes
includ
vitro
vivo
studi
tabl
cholesterol
conjug
also
success
appli
coval
inhibitor
deriv
isothiocyan
group
side
chain
asp
target
ly
hrn
interestingli
line
hypothes
mechan
action
cholesterol
conjug
anoth
lipid
enrich
hiv
lipidom
dihydrosphingosin
also
augment
potenc
conjug
hr
peptid
case
one
deriv
hrn
instead
hrc
cholesterolconjug
peptid
show
improv
pharmacokinet
activ
vivo
cholesterol
conjug
also
solv
outstand
problem
peptid
therapeut
short
vivo
halflif
enzym
degrad
rapid
clearanc
effect
way
improv
peptid
pharmacokinet
pk
conjug
lipid
drive
bind
serum
protein
typic
derivat
long
chain
fatti
acid
derivat
cholesterol
also
explor
compar
subcutan
pk
studi
mice
concentr
mgkg
undetect
plasma
h
nm
still
detect
h
inject
concentr
higher
ic
measur
multipl
strain
anoth
exampl
singl
dose
mgkg
cholesterolconjug
inhibitor
nipah
viru
administ
intraperiton
golden
hamster
suffici
achiev
plasma
concentr
higher
vitro
ic
h
singl
intramuscular
inject
mgkg
cholesterolconjug
inhibitor
newcastl
diseas
viru
ndv
administ
chicken
yield
plasma
concentr
nm
h
nm
h
compar
vitro
ic
nm
ic
nm
overal
pk
cholesterolconjug
inhibitor
expect
least
compar
withand
like
better
thanth
pk
enfuvirtid
administ
twice
daili
subcutan
inject
one
possibl
potenti
activ
hrderiv
peptid
inhibitor
exploit
multimer
anoth
modif
implement
nativ
sequenc
peptid
multimer
bring
avid
effect
effect
reduc
k
inhibitor
fusion
protein
complex
increas
potenc
fusion
entri
inhibitor
effect
cholesterol
conjug
increas
k
facilit
encount
peptid
viral
target
protein
complementari
two
modif
therefor
work
concert
reagent
simultan
dimer
peptid
instal
cholesterol
group
onto
describ
figur
trimer
higherord
multim
could
prepar
strategi
maximum
benefit
multimer
achiev
level
dimer
reagent
stabl
upon
prolong
storag
notabl
cysteinecontain
precursor
peptid
use
produc
monomer
cholesterolconjug
peptid
react
cholesterol
dimerform
moieti
enabl
parallel
synthesi
cholesterolconjug
monom
dimer
figur
also
test
parallel
establish
optim
inhibitor
use
reagent
figur
dimer
cholesterolconjug
inhibitor
prepar
hiv
nipah
measl
viru
mv
potent
effect
correspond
cholesterolconjug
monom
potenti
trimer
hiv
peptid
inhibitor
cholesterol
conjug
independ
report
anoth
laboratori
sinc
discoveri
scope
cholesterol
conjug
consider
increas
includ
exampl
retrovirus
paramyxovirus
coronavirus
orthomyxovirus
henipavirus
filovirus
tabl
virus
vivo
efficaci
demonstr
suitabl
anim
model
exampl
porotto
et
al
show
oncedaili
intraperiton
administr
cholesterolconjug
inhibitor
nipah
viru
golden
hamster
establish
model
infect
effect
prevent
would
otherwis
fatal
nipah
viru
enceph
prophylact
treatment
efficaci
initi
day
viral
challeng
efficaci
initi
concurr
infect
notabl
light
highli
lethal
natur
viru
treatment
day
infect
led
surviv
anim
laboratori
use
intranas
infect
mv
suckl
mice
express
human
slam
transgen
model
evalu
efficaci
cholesterolconjug
hrderiv
peptid
infect
mv
caus
lethal
acut
neurolog
syndrom
complet
prevent
anim
prophylact
oncedaili
administr
cholesterolconjug
dimer
deriv
sequenc
mv
hrc
domain
li
et
al
use
cholesterol
conjug
improv
potenc
previous
describ
inhibitor
ndv
intramuscular
inject
cholesterolconjug
peptid
day
viru
infect
everi
day
protect
chicken
differ
serotyp
ndv
moreov
treatment
anim
day
infect
result
protect
two
interest
featur
studi
deserv
comment
first
aforement
three
studi
peptid
detect
brain
h
administr
indic
cholesterol
conjug
may
enabl
penetr
bloodbrain
barrier
difficult
feat
drug
gener
biolog
particular
second
modest
observ
degre
protect
observ
day
postexposur
porotto
et
al
li
et
al
studi
compar
result
report
monoclon
antibodi
ebola
viru
macaqu
efficaci
dose
day
exposur
includ
zmapp
antibodi
cocktail
use
emerg
therapeut
latest
ebola
outbreak
must
note
though
exampl
report
far
come
virus
featur
class
fusion
protein
preval
class
includ
major
pathogen
hepat
c
viru
dengu
viru
belong
class
ii
herp
simplex
viru
belong
class
iii
class
protein
mainli
form
postfus
structur
exemplifi
hiv
figur
class
ii
fusion
protein
character
trimer
hairpin
compos
fusion
loop
locat
tip
elong
place
fusion
peptid
upstream
class
iii
protein
form
trimer
hairpin
combin
central
trimer
core
similar
class
protein
fusion
loop
structur
similar
class
ii
protein
despit
structur
differ
fusion
protein
adopt
hairpin
structur
suscept
inhibit
exampl
although
entri
herp
virus
featur
class
iii
fusion
protein
complex
process
yet
fulli
clarifi
multipl
glycoprotein
involv
sever
laboratori
report
peptid
deriv
hr
region
gb
gh
herp
simplex
viru
type
bovin
herp
viru
type
human
cytomegaloviru
abl
inhibit
infect
dengu
viru
helic
domain
identifi
stem
region
e
protein
class
ii
protein
critic
viru
assembl
entri
peptid
inhibitor
deriv
membranebind
region
describ
one
inhibit
four
viru
serotyp
moreov
de
novo
comput
design
peptid
inhibitor
success
work
xu
et
al
particular
indic
comput
approach
may
yield
candid
peptid
inhibitor
fusion
protein
class
given
ubiquit
import
cholesterolrich
lipid
raft
viral
fusion
expect
cholesterol
conjug
may
enhanc
antivir
potenc
also
peptid
deriv
class
ii
iii
fusion
protein
howev
data
regard
yet
report
combin
bioinformat
lead
identif
lead
id
potencypk
improv
provid
cholesterol
conjug
may
form
basi
rapid
respons
strategi
emerg
viral
diseas
figur
project
would
begin
immedi
genom
new
pathogen
made
avail
lead
id
phase
would
consist
bioinformat
analysi
eg
via
learncoil
multicoil
newli
sequenc
genom
identifi
hr
region
could
last
day
discuss
previou
section
comput
identif
inhibitori
peptid
virus
util
class
ii
iii
fusion
protein
would
less
straightforward
number
candid
peptid
test
like
larger
howev
given
high
throughput
parallel
solidphas
figur
rapid
respons
strategi
base
cholesterolconjug
fusion
inhibitor
sequenc
genom
emerg
viru
hr
region
identifi
bioinformat
correspond
lead
identif
lead
id
phase
lead
optim
lead
opt
phase
candid
hr
peptid
synthes
form
suitabl
precursor
cholesterol
conjug
react
reagent
shown
figur
cholesterolconjug
monom
dimer
test
antivir
activ
lead
opt
cycl
continu
peptid
found
potent
enough
move
largescal
product
peptid
synthesi
modular
cholesterol
conjug
reaction
initi
number
target
sequenc
repres
key
limit
factor
lead
optim
lead
opt
phase
lead
opt
candid
peptid
would
synthes
form
suitabl
precursor
cholesterol
conjug
react
reagent
shown
figur
similar
one
cholesterolconjug
monom
dimer
would
test
antivir
activ
logic
offtheshelf
reagent
immedi
use
variat
reagent
figur
optim
length
linker
join
monom
might
provid
consider
increas
potenc
shown
kay
et
al
haloacetyl
maleimidefunction
core
polyethylen
glycol
spacer
differ
length
could
react
precursor
rapidli
select
potent
inhibitor
lead
opt
cycl
would
continu
peptid
found
potent
enough
move
largescal
product
rel
small
number
candid
peptid
parallel
synthesi
conjug
expect
lead
opt
phase
would
rapid
optim
week
largescal
product
candid
peptid
therapeut
could
begin
immedi
protocol
labscal
largescal
solidphas
peptid
synthesi
essenti
preclin
evalu
formul
anim
pk
predict
human
dose
could
proceed
parallel
good
manufactur
practic
batch
product
abbrevi
preclin
toxicolog
connect
anim
rule
would
justifi
emerg
situat
strategi
outlin
previou
section
could
provid
short
timefram
cholesterolconjug
therapeut
specif
emerg
viru
although
necessarili
optim
drug
new
diseas
would
repres
key
complement
prevent
measur
could
enabl
better
control
initi
outbreak
research
effort
may
lead
substitut
therapi
increas
efficaci
andor
better
eas
administr
one
could
even
envisag
set
core
laboratori
routin
run
lead
id
lead
opt
stage
newli
identifi
virus
potenti
concern
advanc
actual
outbreak
diseas
limit
resourc
necessari
could
part
emerg
prepared
respons
set
center
diseas
control
prevent
http
emergencycdcgov
global
alert
respons
http
wwwwhointcsren
prepar
respond
public
health
emerg
